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The transforming growth factor bs are of major
importance in the wound repair process; however, no
studies to date have investigated the role of the trans-
forming growth factor b receptors in chronic venous
leg ulcers or what effect healing has on these proteins.
To determine whether the transforming growth fac-
tor b peptides and their receptors are expressed in
chronic venous wounds, we used immuno¯uorescent
analysis and quantitative competitive reverse tran-
scription polymerase chain reaction to identify the
protein and mRNA expression, respectively. Biopsy
samples from wounds and normal skin were collected
from 12 patients with chronic venous leg ulcers and
three patients undergoing reconstructive surgery,
respectively. Additionally four of the chronic venous
leg ulcer patients were re-biopsied between 2 and
8 wk after the ®rst biopsy when the wounds had
entered the healing phase. The tissue excised from the
ulcers included the surrounding intact skin, the ulcer
edge, and the ulcer base. Immuno¯uorescent staining
for transforming growth factors b1, b2, and b3 was
observed within the epidermis of the skin surrounding
the chronic venous ulcers and in ®broblasts and
in¯ammatory cells of the dermis, although this stain-
ing was not as strong as that seen in normal
unwounded skin. Very little staining could be seen
within the ulcers for any of the ligands, however. In
contrast the transforming growth factor b type I
receptor was observed throughout the ulcers and the
normal unwounded skin biopsies, particularly in the
basal epidermal cells. No immuno¯uorescence for the
type II transforming growth factor b receptor was
observed in any of the ulcer biopsies investigated,
although it was observed throughout the epidermis
and in ®broblasts and in¯ammatory cells in the sur-
rounding skin. Quantitative, competitive reverse
transcription polymerase chain reaction was used to
analyze mRNA expression for transforming growth
factor b1 and the type II receptor in the nonhealing
ulcers and normal unwounded skin biopsies. These
studies revealed that transforming growth factor b1
and transforming growth factor b receptor II mRNA
was expressed in all the chronic nonhealing ulcers
albeit at very low levels for the type II receptor. In
marked contrast to the staining observed in nonheal-
ing chronic ulcers, positive immunostaining was
observed for the transforming growth factor bs and
both the type I and type II receptors in healing ulcers.
These results suggest that the absence of a viable
receptor complex for the transforming growth factor
bs in nonhealing chronic venous ulcers may con-
tribute to wound chronicity. Key words: healing/
immuno¯uorescence/RT-PCR/wound. J Invest Dermatol
117:1282±1289, 2001
V
enous ulceration is the result of chronic venous
insuf®ciency leading to increased pressure in the
venous system (Angle and Bergan, 1997). The link
between venous hypertension and venous ulcera-
tion is incompletely understood, however. It has
been suggested that extravasation of plasma proteins including
®brinogen, which polymerizes around dermal capillaries to form
``®brin cuffs'', impedes the diffusion of oxygen and nutrients to
the dermis and inhibits capillary sprouting. These cuffs have
been shown to contain other serum proteins including a2-
macroglobulin and factor XIIIa as well as the matrix proteins
laminin, ®bronectin, tenascin, and collagens I and III, suggesting
that components of the cuffs are actively synthesized by
surrounding connective tissue cells (Herrick et al, 1992).
Alternatively, increased pressure in the venous system, which
reduces the perfusion pressure and capillary ¯ow rate, may
result in the trapping of white blood cells in distal leg capillaries
(Coleridge Smith et al, 1988). It is proposed that these trapped
leukocytes become activated and release toxic metabolites,
enzymes, and cytokines, damaging endothelial cells and allowing
passage of plasma proteins. In addition, the trapped leukocytes
may cause local areas of ischaemia.
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The role of growth factors in chronic venous wound healing is
poorly understood. Several studies have demonstrated decreased
growth factor activity in the chronic wound environment that may
contribute to reduced amounts of extracellular matrix synthesis and
collagen production (Cooper et al, 1994; Higley et al, 1995). The
colocalization of serum binding proteins and growth factors, e.g.,
a2-macroglobulin and transforming growth factor b (TGF-b), in
®brin cuffs has led to the suggestion that the trapping or
inactivation of growth factors essential to the wound repair process
renders them unavailable to the cells of wound repair (Falanga,
1993; Higley et al, 1995). Other studies suggest that the pro-
in¯ammatory environment of the ulcer promotes the degradation
of growth factors and their receptors (Wallace and Stacey, 1998).
Agren et al (1999) have revealed that venous-ulcer-derived
®broblasts in culture have reduced growth activity and are less
responsive to platelet-derived growth factor. Additionally, in vitro
studies have revealed venous-leg-ulcer-derived ®broblasts are
unresponsive to TGF-b1 and this is associated with reduced levels
of the type II TGF-b receptor (Hasan et al, 1997).
In normal acute wounds, studies have revealed the importance of
the TGF-bs to stimulate the synthesis of multiple extracellular
matrix components, including collagens, ®bronectin, vitronectin,
tenascin, and proteoglycans, reviewed by O'Kane and Ferguson
(1997). Additionally they suppress matrix degradation by down-
regulating the expression of proteases, such as plasminogen
activators (Laiho et al, 1986), collagenase (Edwards et al, 1987),
and stromelysin (Kerr et al, 1990), and induce protease inhibitors,
such as plasminogen activator inhibitor 1 (Laiho et al, 1986; 1987)
and tissue inhibitor of metalloproteases (Edwards et al, 1987).
Numerous studies have shown that exogenously applied TGF-bs
enhance and accelerate acute wound healing (Mustoe et al, 1987;
Shah et al, 1995), especially in situations where the normal healing
process is naturally or arti®cially impaired (Cox et al, 1992). TGF-
b1 and TGF-b3 are both expressed in the thickened epidermis of
both acute wounds and decubitus ulcers indicating a possible role in
epidermal maintenance and reepithelialization (Schmid et al, 1993).
The action of the TGF-bs is mediated by a complex formed
through binding to two speci®c high-af®nity transmembrane
serine±threonine kinases (Ebner et al, 1993). The type I receptor
requires the type II receptor to bind ligand, whereas the type II
receptor requires the type I receptor for signaling (Wrana et al,
1992; Inagaki et al, 1993). Expressions of both the type I and type II
TGF-b receptors are increased in response to acute wounding
(Frank et al, 1996), and it has been suggested that excessive scarring
may be associated with failure to eliminate TGF-b receptor over-
expressing ®broblasts during granulation tissue remodeling, leading
to overproduction of matrix proteins and subsequent ®brosis
(Schmid et al, 1998).
Despite signi®cant investment in the clinical trialing of the
TGF-b isoforms on chronic wounds, to date no studies have
investigated TGF-b receptor expression in chronic venous leg
ulcers. Additionally, no studies have determined the effect of
healing on the growth factor and receptor expression in these
wounds. The aim of this study was to describe the expression of the
TGF-b isoforms and their receptors in the wound bed and margin
of the chronic venous ulcer and compare this expression to that
seen in normal skin. Additionally the effect of healing on the
growth factor and receptor pro®le was also assessed.
MATERIALS AND METHODS
Venous leg ulcer biopsies and normal skin samples Skin samples
were collected from a total of 12 patients with chronic venous leg ulcers
on their ®rst presentation at the wound healing clinic at the Queen
Elizabeth Hospital, Adelaide. Informed consent was obtained from
individual subjects for all procedures that were approved by the Ethics of
Human Research Committee of the Queen Elizabeth Hospital, Adelaide.
The diagnosis of venous ulcer was based on an ankle brachial index of
> 0.7, a toe pressure of > 40 mmHg on the limb of the target ulcer, and
absence of diabetes. Patients were between 47 and 86 y of age and ulcer
duration ranged from 18 mo to 9 y. Biopsies (10 3 3 mm) were taken
under local anesthetic from the margins of the chronic venous ulcers and
included wound margin epithelium and surrounding dermal and
epidermal tissue. Wound margin biopsies were embedded in (Tissue-
Tek) OCT compound (Sakura Finetek, CA) and frozen in liquid
nitrogen. In addition, 6 mm punch biopsies were taken under local
anesthetic from the center of the ulcers and immediately frozen in liquid
nitrogen for later RNA extraction. All ulcer samples were stored at
±70°C until required. Four of the patients consented to an additional
biopsy being taken within 2±8 wk after the initial presentation when the
ulcers had entered the healing phase as determined by measuring the area
of the wound, the appearance of healthy granulation tissue, and increased
epithelial coverage of the wound. The ulcers had reduced in size to
between 87% and 18% of their original wounded area. During weekly
visits to the clinic the wounds were washed using a Medisponge (LMI,
MI) containing 0.25% chlorohexidene; moisturizer was applied to the
intact skin, blunt debridement was performed as necessary, and the
wounds were dressed with Profore (Smith and Nephew, U.K.) according
to the manufacturer's directions. Normal skin samples (2 cm 3 1 cm)
were obtained from three patients undergoing reconstructive plastic
surgery. Immediately upon removal from the patients, half of the tissue
was frozen in liquid nitrogen, and the other half was embedded in OCT
compound and frozen as before.
Immuno¯uorescence studies Indirect immuno¯uorescent localization
was used with a biotin±streptavidin ampli®cation step for increased
sensitivity. Serial 7 mm cryosections were washed with phosphate-
buffered saline (PBS) and incubated for 1 h at room temperature with
TGF-b1, TGF-bRI, TGF-bRII primary antibodies (all Santa Cruz
Biotechnology, CA; 1:100) or TGF-b2, TGF-b3 (R&D Systems, MN;
1:100) for 1 h at room temperature. After three washes in PBS, sections
were incubated with either biotinylated sheep antirabbit (Sigma-Aldrich,
Sydney, Australia; 1:200) or biotinylated rabbit antigoat (Zymed
Laboratories, CA; 1:200) for 1 h at room temperature. After further
washing with PBS, CY3-conjugated streptavidin (Sigma-Aldrich; 1:500)
was applied to all sections for 1 h. After ®nal washes in PBS, slides were
mounted in Immunmount (Shandon, PA) and examined using a
¯uorescent microscope. CY3 emits ¯uorescence at 570 nm, which is
visualized as red staining in positive regions. Images were captured and
viewed using Image-Pro Plus V3.1 software (Media Cybernetics, MD).
For veri®cation of staining, negative controls included preadsorption of
the TGF-b1, TGF-b2, TGF-b3 antibodies with excess amounts of
human TGF-b1, TGF-b2, and TGF-b3 (10 ng per ml) or control
blocking peptides for TGF-bRI and TGF-bRII (sc-399P, sc-400P; Santa
Cruz Biotechnology), for 1 h at room temperature. On additional
control sections, primary antibodies were replaced by either normal
rabbit IgG or normal goat IgG as appropriate or the primary and
secondary antibodies were omitted to determine nonspeci®c binding. No
positive staining for any of the peptides investigated was seen on any of
the control sections.
Quantitative competitive reverse transcription polymerase chain
reaction (RT-PCR) Escherichia coli were transformed with the
pEGFTGF plasmid (Tarnuzzer et al, 1996), and the plasmid DNA was
isolated and linearized for RNA transcription. The RNA was puri®ed by
poly-A selection and a template dilution series prepared as described
previously (Tarnuzzer et al, 1996). A 10-fold dilution series in the range
2 3 109±2 3 104 copies of RNA template per ml was then constructed
by diluting the competitive RNA template sample in DEPC water.
Primer sequences were synthesized as follows: b-actin, antisense 5¢-
CTCAATGTCACGCACGATTTC-3¢, sense 5¢-GTGGGGCGCCCC-
AGGCACCA-3¢, 540 bp; TGF-b1, antisense 5¢-GATGCTGGGCCC-
TCTCCAGC-3¢, sense 5¢-CAAGCAGAGTACACACAGCA-3¢,
442 bp; TGF-bRII, antisense 5¢-GATCTTGACTGCCACTGTCTC-3¢,
sense 5¢-TGTGTTCCTGTAGCTCTGATG-3¢, 430 bp.
Competitive RT-PCR Total RNA was extracted from six ulcer biopsies
using a Quickprep Total RNA Extraction kit (Amersham Pharmacia
Biotech, Uppsala, Sweden). One microgram was reverse transcribed in a
series of 20 ml reactions with known dilutions of pEGFTGF competitive
RNA (2 3 104±2 3 109 copies), 250 ng oligo(dT)16, and 20 U RNasin.
The reaction was heated to 65°C for 15 min in a GeneAmpâ PCR
System 9700 thermal cycler (PE Applied Biosystems, Norwalk, CT).
Following denaturation of the RNA, reverse transcription buffer
(50 mM Tris-HCl, pH 8.3, at 25°C, 50 mM KCl, 10 mM dithiothreitol,
0.5 mM spermidine), 1.5 mM MgCl2, 0.2 mM dNTPs, 15 U AMV
reverse transcriptase, and nuclease-free water to a ®nal volume of 20 ml
was added to the reaction. Reverse transcription was performed at 42°C
for 60 min followed by 95°C for 10 min. To determine mRNA levels
of TGF-b1, TGF-bRII, and b-actin, cDNA products were subjected to
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PCR using primers described earlier. DNA ampli®cation was performed
in a 50 ml volume containing 2 ml of the reverse transcription reaction,
1 3 PCR buffer (50 mM KCl, 10 mM Tris-HCl, pH 9.0, 0.1%
TritonâX-100), 1.5 mM MgCl2, 200 mM dNTPs, 50 pmol of each
antisense and sense PCR primer, and 2.5 U Taq polymerase. PCR
conditions were 94°C for 5 min, followed by 41 cycles of 94°C for
1.5 min, 58°C for 2 min, 72°C for 3 min, and 72°C ®nal extension for
10 min. PCR products were separated on 1.5% agarose gels containing
25 ng per ml ethidium bromide at 90 V for approximately 1.5 h. The
gels were visualized under ultraviolet light, and images were captured
using an ImageMasterâ VDS thermal imaging system (Amersham
Pharmacia Biotech). The integrated optical density of bands was
determined using ImageMaster VDS software (Amersham Pharmacia
Biotech). Intensity values were normalized for their molecular weight,
and the log of the ratio of the band intensities within each lane was
plotted against the log of copy number of template added per reaction.
The number of molecules of target message was determined where the
ratio of template and target band intensities was equal to 1.
RESULTS
All the biopsy sites within the venous ulcers healed without
complication. Indeed, biopsy wounds extending through the
wound margin were noted to heal more quickly than the ulcer
margin itself. An example of a hematoxylin and eosin (H&E)
stained ulcer wound margin biopsy is shown in Fig 1(A). Features
characteristic of chronic venous ulcers were noted in all wounds
studied. The ulcer wound base was characterized by areas of
vascular granulation tissue overlying disorganized collagen bundles.
A prominent in¯ammatory in®ltrate was present in most wounds,
often extending into the surrounding dermis. Characteristic
hemosiderin deposits and capillary cuf®ng were noted. The
epithelial margin was characterized by a marked hyperplastic
acanthosis. An example of normal skin stained with H&E is shown
in Fig 1(B). Representative H&E stained views of normal skin,
ulcer margin, and ulcer base (Fig 1C±E, respectively) represent
the views shown in the subsequent immuno¯uorescent studies
(Figs 2, 3). Twelve chronic nonhealing ulcers, four healing
ulcers, and three normal skins were examined for TGF-b1,
TGF-b2, TGF-b3, TGF-bRI, and TGF-RII, and representative
pictures of the staining observed in all of these tissues are shown in
Figs 2 and 3.
Expression of TGF-b and its receptors in chronic wounds
and normal unwounded skin Immuno¯uorescent stained
sections of normal unwounded skin revealed the presence of
TGF-b1 particularly throughout the epidermis and within
®broblasts within the dermis (Fig 2A). At the margins of the
ulcers, there was obvious TGF-b1 staining in the thickened
epidermis, the epithelium of hair follicles, and ®broblasts (Fig 2B).
Staining of TGF-b1 within the ulcers was markedly reduced,
however (Fig 2C). In addition, TGF-b1 expression in the
epidermal margin of the ulcers was reduced compared to that
seen in normal epidermis (Fig 2A). In the healing ulcers, positive
staining for TGF-b1 was observed particularly around blood vessels
and ®broblasts (Fig 2D).
TGF-b2 immuno¯uorescence showed a different distribution to
that observed for TGF-b1. In normal unwounded skin TGF-b2
immunoreactivity was observed in suprabasal epidermal cells and in
®broblasts within the dermis (Fig 2E). In contrast, no staining was
observed in the epidermal margin of the ulcers, although ®broblasts
and in¯ammatory cells within the dermal wound margins were
TGF-b2 positive (Fig 2F). The intensity of the TGF-b2 staining
was markedly reduced within the ulcers compared to normal
dermis or the wound margin (Fig 2G). In contrast to the
nonhealing ulcers, the healing ulcers showed marked cellular
staining for TGF-b2, particularly in ®broblasts within the
granulation tissue of the wounds (Fig 2H).
Figure 1. Histology of chronic venous leg
ulcers and normal skin. Biopsies from chronic
venous leg ulcers and normal skin were ®xed in
formalin, embedded in paraf®n wax, sectioned,
and stained with H&E to reveal the cellular
morphology of the tissues. Due to the size of the
ulcer biopsies a composite picture was made from
15 individual views and a montage created using
ImageMaster software (see Materials and Methods).
A representative montage of a typical venous ulcer
is shown in (A) with the ulcer margin on the left
of the picture. Normal skin is shown in (B), and
higher magni®cation pictures are shown of the
normal skin (C), skin adjacent to the ulcer (D),
and ulcer tissue (E). The boxes in (A) and (B)
indicate the position of the higher magni®cation
pictures. Scale bar: (A, B) 200 mm, (C±E) 50 mm.
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TGF-b3 immunostaining was observed throughout the epider-
mis and in ®broblasts in normal unwounded skin (Fig 2I).
Reduced epidermal staining was observed at the margins of the
ulcers with in¯ammatory cells staining positive at the dermal ulcer
edge (Fig 2J). No staining was observed within any of the
nonhealing ulcers investigated (Fig 2K). In contrast, clear positive
staining was observed in all of the healing ulcers (Fig 2L).
The expression of TGF-b receptors was examined in biopsies
from chronic venous ulcers and compared to that in normal
unwounded skin and healing ulcers. TGF-b type I receptor
immunostaining was restricted to the basal epidermal cells of
normal skin with very little staining evident in the suprabasal layers
(Fig 3A). Minimal staining was observed in the dermis of normal
skins. In contrast, intense type I receptor expression was seen
throughout the thickened epidermal margin of the ulcers, including
the suprabasal layers, and within ®broblasts in the dermal ulcer
margin (Fig 3B). Furthermore, strong immunoreactivity was
observed in the ulcer bed with ®broblasts and in¯ammatory cells
staining positive for TGF-b type I receptor (Fig 3C). In the
healing ulcers, positive staining for this receptor was again observed
in the ®broblasts and in¯ammatory cells of the ulcer bed (Fig 3D).
The pattern of the type II receptor expression was markedly
different to that observed for the type I receptor. Type II TGF-b
receptor immunostaining was observed throughout the epidermis
and in ®broblasts within the dermis of unwounded skins (Fig 3E),
a pattern similar to TGF-b1 and TGF-b3. Diminished staining was
observed in the epidermal margins of the ulcers, although
in¯ammatory cells and ®broblasts in the dermal margins were
type II receptor positive (Fig 3F). In marked contrast to the type I
receptor, no type II receptor immunostaining was observed within
the ulcers themselves (Fig 3G). Immuno¯uorescent staining for
TGF-b type II receptor in the healing ulcers revealed that
®broblasts within the ulcer were now staining positive for the
receptor, a result similar to that observed for the ligands (Fig 3H).
This absence of the TGF-bs and their receptor expression in
nonhealing ulcers and the expression of these factors in healing
ulcers were found to be consistent between patients. Figure 4
shows staining patterns observed for TGF-b1 and the type II
receptor. In all four nonhealing ulcers, no expression of TGF-b1
was observed (Figs 1C, 4A, E, I), whereas, in marked contrast,
staining was observed in healing ulcers from the same patients in
®broblasts and in¯ammatory cells (Figs 1D, B, F, J). Similarly, in
all four nonhealing ulcers, no expression of the type II receptor was
observed in the nonhealing ulcers (Figs 2G, C, G, K) whereas
®broblasts and in¯ammatory cells stained positive in the healing
ulcers from the same patients (Figs 2H, D, H, L).
Quantitative competitive RT-PCR analysis The apparent
loss of immunoreactivity for TGF-b1 and the type II receptor
within chronic venous ulcers led us to further investigate the
mRNA expression of these proteins using quantitative competitive
RT-PCR (Tarnuzzer et al, 1996). Quantitative RT-PCR
ampli®cation was undertaken in the presence of increasing
dilutions of a competitive template containing 337 bp sequences
corresponding to TGF-b1, TGF-bRII, and b-actin mRNA
(Tarnuzzer et al, 1996). The same reverse transcription reaction
for each RNA sample was used to amplify all three genes under
investigation. Ampli®cation of the template produces a product of
337 bp that increases in intensity at the expense of the mRNA
message in the biopsy samples with decreasing dilution. Expression
of b-actin mRNA was detected in all normal and ulcer samples,
con®rming the integrity of the mRNA from the ulcer biopsies
Figure 2. Immuno¯uorescent staining of the TGF-bs in unwounded normal skin and nonhealing and healing chronic venous ulcers. The
unwounded normal skins and ulcer biopsies were stained using antibodies to TGF-b1, TGF-b2, and TGF-b3. Representative staining of normal skin (A,
E, I), ulcer edge (B, F, J), nonhealing ulcer (C, G, K), and healing ulcer (D, H, L) is shown. TGF-b1 immuno¯uorescent staining is shown
in (A), (B), (C), (D), TGF-b2 in (E), (F), (G), (H), and TGF-b3 in (I), (J), (K), (L). Scale bar: 50 mm.
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(Fig 5). The number of copies of b-actin mRNA per mg total
RNA ranged from 1.5 3 106 to 1.3 3 107 (6.6 3 106 6
3.9 3 106 mean 6 SEM) in normal skin and from 1.0 3 106 to
2.6 3 107 (63.9 3 106 6 3.9 3 106 mean 6 SEM) in ulcer tissue.
The expression of TGF-b1 mRNA was observed in all samples
from normal skin and in ®ve out of six of the biopsy samples from
the base of the ulcers, producing the expected product at 442 bp
(Fig 5). The mean copy number for the normal samples was
1.2 3 105 6 1.0 3 105 (mean 6 SEM) copies TGF-b1 mRNA
per mg total RNA compared to 9.5 3 104 6 5.7 3 104 (mean
6 SEM) copies per mg total RNA extracted from the ulcer samples.
PCR ampli®cation of the TGF-bRII gene from RNA extracted
Figure 4. Immuno¯uorescent staining of TGF-b1, TGF-bRII in nonhealing and healing chronic venous ulcers. Nonhealing and
healing venous ulcer biopsies taken from the same patients were stained using antibodies to TGF-bI and TGF-bRII. Three patients' biopsies
are shown: Patient 1 (A±D), Patient 2 (E±H), Patient 3 (I±L). TGF-b1 staining is shown in nonhealing ulcers (A, E, I) and healing ulcers
(B, F, J). TGF-bRII staining is shown in nonhealing ulcers (C, G, K) and healing ulcers (D, H, L). Scale bar: 50 mm.
Figure 3. Immuno¯uorescent staining of the TGF-b type I and II receptors in unwounded normal skin and nonhealing and healing
chronic venous ulcers. The unwounded normal skins, ulcer biopsies, and healing ulcer biopsies were stained using antibodies to TGF-bRI and TGF-
bRII. Representative staining of the normal skin is shown in (A) and (E), ulcer edge (B, F), ulcer tissue (C, G) and healing ulcer (D, H). TGF-bRI
immuno¯uorescent staining is shown in (A), (B), (C), and (D), and TGF-bRII in (E), (F), (G), and (H). Scale bar: 50 mm.
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from the ulcer biopsies revealed no expression in six of six wounds
(Fig 5). Only the 337 bp template could be seen serving as a
positive control for the PCR reactions. TGF-bRII PCR product at
the expected 430 bp was observed in normal skin (Fig 5). To
increase the sensitivity of the quantitative RT-PCR technique to
detect very low levels of mRNA production we enriched the
reverse transcription procedure by the use of a targeted 3¢ primer
for the gene of interest in the reverse transcription reaction. Using
this selective procedure we found that all of the six ulcer tissues
expressed low levels of the TGF-b type II receptor (Fig 5).
DISCUSSION
This study has revealed that the levels of all the TGF-b ligands are
reduced in nonhealing venous leg ulcers and also that there is
differential expression of the TGF-b receptors within these chronic
wounds compared with normal, unwounded tissue. We observed
no TGF-bRII receptor protein in any of the 12 chronic venous
ulcers studied and low level expression of the TGF-bRII gene.
Conversely, we observed expression of the type I receptor
particularly at the wound margins and within the ulcers.
Although the type I receptor staining was restricted to the basal
cells within the epidermis of the normal unwounded skin, it was
observed throughout the thickened epidermis in the skin sur-
rounding the ulcers. The low level expression of the ligands and the
absence of TGF-bRII protein in the ulcers could be important
because for the TGF-b ligands to have any of their numerous
wound healing activities they require the formation of a
heterodimeric signaling complex (Derynck and Feng, 1997;
Miyazono, 2000). The mechanism involved in TGF-b signaling
involves the binding of the ligand to the type II receptor, which
then recruits the type I receptor into the complex thereby forming
a heteromeric complex of two TGF-bRIIs and two TGF-bRIs
(Piek et al, 1999). Therefore, if one member of the TGF-b receptor
complex is absent, as the TGF-bRII is in these nonhealing venous
ulcers, we would expect receptor signaling to be compromised and
neither endogenous nor exogenous TGF-b ligand would have its
expected effects on wound repair. In support of our in vivo
observations, in vitro studies have shown that venous-ulcer-derived
®broblasts are unresponsive to TGF-b1 and that this responsiveness
is associated with a 4-fold decrease in TGF-b type II receptors
(Hasan et al, 1997).
The appearance of the epidermis surrounding the ulcers was very
different to that seen in normal skin or in acute wounds. Markedly
thickened, acanthotic, hyperplastic epidermis was observed at the
ulcer wound margins. This type of epidermal appearance has been
interpreted to be regenerative or proliferative rather than migratory
(Falanga et al, 1994). As TGF-b switches keratinocytes from a
differentiating to a regenerative phenotype (Nickoloff et al, 1988),
reduced TGF-b activity in the epidermal wound margins may
result in continued proliferation and differentiation, rather than
migration across the wound bed. It has been revealed that the loss
of TGF-b1, or SMAD3, a component of the TGF-b signaling
system, actually enhances reepithelialization in acute wounds (Koch
et al 2000; Ashcroft et al, 1999; respectively). Therefore the reduced
epithelialization observed in chronic venous leg ulcers is unlikely to
be due only to the reduced expression of the TGF-bs or their
receptors. In fact it is likely that other factors may contribute
signi®cantly to the inhibition of wound closure in ulcers compared
to acute wounds. For example, TGF-b stimulates ®bronectin
production in ®broblasts (Ignotz and MassagueÂ, 1986) and
keratinocytes (Clark et al, 1982), and studies have revealed that
®bronectin is absent in the matrix of chronic nonhealing ulcers
(Herrick et al, 1992). As ®bronectin is required within the
provisional matrix for epithelial migration to occur (Clark et al,
1982), the reduced expression of the TGF-bs in conjunction with
low expression of ®bronectin could inhibit the reepithelialization of
chronic wounds and could lead to the thickened epidermis
observed surrounding the ulcers. Interestingly, although TGF-b1
and TGF-b3 staining was observed in epidermal cells adjacent to
the ulcers, TGF-b2 staining was restricted to the suprabasal
epidermal cells and was much reduced in the surrounding skin of
the ulcers compared to normal unwounded skin. The reason for
this difference in ligand expression may re¯ect different functions
for the TGF-bs in epidermal cells and may further point to the
different wound healing activities that the TGF-b ligands possess
(Shah et al, 1995).
The method of quantitative competitive RT-PCR, developed
by Tarnuzzer et al (1996), was used to detect the expression of
mRNA for TGF-b1, TGF-bRII, and b-actin. This procedure has
been successfully used to determine mRNA levels in dermal wound
biopsies (Tarnuzzer and Schultz, 1996; Ashcroft et al, 1997) and
requires only low levels of mRNA, which was an important
consideration due to the size of the biopsies taken from the venous
ulcers. Although large variations were observed between mRNA
obtained from different ulcer patients, due perhaps to variations in
ulcer age and size, we observed expression of mRNA for TGF-b1
in all of the ulcer samples. As negligible protein was detected using
immuno¯uorescent staining, however, the mRNA may not be
being transcribed and translated into protein or the peptide may be
degraded by proteases within the chronic wound environment.
Previous studies have shown that there are high levels of proteases
in chronic wound ¯uid (Yager et al, 1996; Herrick et al, 1997), and
additional studies have also shown that chronic wound ¯uid can
readily degrade growth factors and their receptors (Bennett and
Schultz, 1993).
In contrast to the readily detectable expression of mRNA for
TGF-b1, no expression of the TGF-bRII was seen in any of the six
Figure 5. Ethidium bromide stained gels showing RT-PCR ampli®cation of cellular RNA and template RNA for TGF-b1, TGF-b type
II receptor and b-actin in normal skin and chronic venous leg ulcers. Representative gels showing gene products for TGF-b1 and TGF-bRII
in nonhealing chronic ulcers (U) and normal skin samples (N) are shown. Enrichment of the reverse transcription reaction for TGF-bRII is shown in
the third panel (E-TGF-bRII) for both the ulcers and normal skin samples. The markers are shown in lane 1, and lanes 2±7 show ampli®cation of
decreasing amounts of reverse transcribed template RNA (2 3 109±2 3 104 copies, respectively) in the presence of 1 mg total RNA. The 337 bp band
is the RT-PCR ampli®cation of template RNA; the higher molecular weight band represents the ampli®cation of TGF-b1 (442 bp), TGFbRII
(430 bp), and b actin (540 bp).
VOL. 117, NO. 5 NOVEMBER 2001 TRANSFORMING GROWTH FACTOR b EXPRESSION IN CHRONIC VENOUS ULCERS 1287
ulcers investigated using conventional RT-PCR, but when an
enrichment protocol to select for TGF-bRII was used gene
expression was observed. This indicates that either the cells within
the ulcers have reduced ability to produce mRNA for the type II
receptor or that the mRNA is unstable and being degraded.
Additionally, the absence of protein expression for the type II
receptor in nonhealing ulcers could indicate that the mechanism
involved may also be one of transcriptional suppression, particularly
as re-expression of this receptor is observed in healing ulcers.
Diminished cellular responsiveness to TGF-bs has frequently been
correlated with decreased transcription of the type II receptor gene
(Bae et al, 1995). In keratinocytes, the mechanism involved in this
transcriptional downregulation of the TGF-bRII gene has been
shown to involve decreased interaction between transcription
factor proteins and their target sequences within positive regulatory
elements of the TGF-bRII promoter (Kim et al, 1997). Further
characterization of the promoter region of the TGF-bRII gene has
also revealed the existence of a negative cis-regulatory element that
can inhibit transcription of this gene (Song et al, 2001).
Reduced expression of the TGF-b type II receptor has been
observed in other wound repair pathologies. Mice treated with
glucocorticoids have impaired wound healing responses and studies
have revealed that there is differential expression of the TGF-b
receptors in these wounds with low levels of the type II receptor
detected (Frank et al, 1996). Also in ®brotic lesions associated with
athersclerosis, the normal antiproliferative effects of TGF-b1 on
vascular cells is reduced and there is a concomitant reduction in the
expression of the type II receptor (McCaffrey, 2000).
The addition of exogenous TGF-bs to chronic wounds has been
suggested as a potential therapeutic modality. This is due to their
ability to enhance the normal repair process in animal models by
increasing the degree of cellularity and the rate of angiogenesis,
stimulating keratinocyte migration and increasing the amount of
collagen accumulated. Despite several clinical studies having been
performed using recombinant TGF-bs, however, to date no TGF-
b based preparation is on the market or near market approval.
Suggestions for this lack of signi®cant clinical ef®cacy have included
problems with the delivery vehicle, the dose, or the length of
application (Robson, 1997). Given the results obtained in this study
we propose that another factor to consider is the level of TGF-b
receptor expression in chronic dermal wounds. Importantly,
following the implementation of good wound management the
pro®le of the TGF-bs and their receptors more closely resembles
that observed in the acute wound (Frank et al, 1996; Gold et al,
1997).
In summary, this study has revealed that the levels of all the
TGF-b ligands are reduced in venous leg ulcers and also that there
is differential expression of the TGF-b receptors within these
chronic wounds compared with normal, unwounded tissue. We
postulate that the absence of a viable receptor complex could be
important in the chronicity of venous ulceration and may account
for the reduced proliferation and increased degradation that is
symptomatic of chronic wound healing. Once an ulcer has entered
a healing phase expression of TGF-b and its receptors is
upregulated and at this stage exogenous addition of growth factors
may be more effective. This could be of particular importance in
the clinical trialing of growth factors for their effects on impaired
wound healing.
We thank Helen Hughes for all her help and assistance in the Wound Healing
Clinic and Kaylene Pickering for technical expertise.
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